New genome-editing technology to help treat blood cancers

March 13, 2015, Walter and Eliza Hall Institute
Australian researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.Dr Brandon Aubrey, Dr Gemma Kelly and Dr Marco Herold (L-R) from the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia, led the research.Using the technology they were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival. Credit: Walter and Eliza Hall Institute of Medical Research.

Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.

Using the technology, researchers from the Walter and Eliza Hall Institute were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival.

The research, published in the journal Cell Reports, provides a 'proof of concept' for using the technology as a direct treatment for human diseases arising from genetic 'errors'.

Dr Brandon Aubrey, Dr Gemma Kelly and Dr Marco Herold adapted the technology, called CRISPR, to specifically mimic and study blood cancers. The Walter and Eliza Hall Institute has one of the most advanced CRISPR laboratories in Australia, established and led by Dr Herold.

Dr Aubrey, who is also a haematologist at The Royal Melbourne Hospital, said the team used the CRISPR technology to target and directly manipulate genes in blood .

"Using preclinical models, we were able to kill human Burkitt lymphoma cells by deleting MCL-1, a gene that has been shown to keep cancer cells alive," he said. "Our study showed that the CRISPR technology can directly kill cancer cells by targeting factors that are essential for their survival and growth. As a clinician, it is very exciting to see the prospect of new technology that could in the future provide new treatment options for cancer patients."

The CRISPR/Cas9 system works by efficiently locating and targeting particular genes of interest in the whole genome. It can either target the gene to introduce mutations that make the gene non-functional, or introduce changes that make mutated genes function normally again.

Dr Herold said pharmaceutical companies around the world were already investing millions of dollars to develop CRISPR as a tool for treating genetic diseases such as cancer.

"There is a lot of excitement and a significant amount of resources being invested worldwide to use CRISPR technology for treating patients," Dr Herold said. "The technology can directly target any gene in the person's genome, therefore overcoming many common drug development problems.

"In our study, we showed for the first time that it is possible for CRISPR technology to be used in cancer therapy, however CRISPR is a unique approach that could potentially be used for treating any disease that is caused by genetic mutations. The speed at which we are now able to make specific changes in the DNA will also accelerate basic research discoveries in the lab," Dr Herold said.

More than 50 research groups from around Australia have sought Dr Herold's expertise and are working with the laboratory to adapt the technology for their own research.

Dr Herold said CRISPR was a very new technology with many advantages over existing tools. "CRISPR is a rapid, easy and efficient technology with the best results for genome editing," he said.

"In addition to its very exciting potential for disease treatment, we have shown that it has the potential to identify novel mutations in cancer-causing genes and genes that 'suppress' cancer development, which will help us to identify how they initiate or accelerate the development of cancer.

"The technology dramatically shortens the time frame for fundamental research, allowing us to speed up the discoveries that could be translated to better diagnostics and treatments for the community."

Explore further: In vivo CRISPR-Cas9 screen sheds light on cancer metastasis and tumor evolution

Related Stories

In vivo CRISPR-Cas9 screen sheds light on cancer metastasis and tumor evolution

March 5, 2015
For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome. A team of scientists at the Broad Institute and MIT's David H. Koch Institute ...

Cellular scissors chop up HIV virus

March 10, 2015
Imagine a single drug that could prevent human immunodeficiency virus (HIV) infection, treat patients who have already contracted HIV, and even remove all the dormant copies of the virus from those with the more advanced ...

Recommended for you

Researchers use a molecular Trojan horse to deliver chemotherapeutic drug to cancer cells

February 23, 2018
A research team at the University of California, Riverside has discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

Lab-grown 'mini tumours' could personalise cancer treatment

February 23, 2018
Testing cancer drugs on miniature replicas of a patient's tumour could help doctors tailor treatment, according to new research.

An under-the-radar immune cell shows potential in fight against cancer

February 23, 2018
One of the rarest of immune cells, unknown to scientists a decade ago, might prove to be a potent weapon in stopping cancer from spreading in the body, according to new research from the University of British Columbia.

Study tracks evolutionary transition to destructive cancer

February 23, 2018
Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. Mutation and selective pressure—cornerstones of Darwin's theory—are the means ...

Putting black skin cancer to sleep—for good

February 22, 2018
An international research team has succeeded in stopping the growth of malignant melanoma by reactivating a protective mechanism that prevents tumor cells from dividing. The team used chemical agents to block the enzymes ...

Cancer risk associated with key epigenetic changes occurring through normal aging process

February 22, 2018
Some scientists have hypothesized that tumor-promoting changes in cells during cancer development—particularly an epigenetic change involving DNA methylation—arise from rogue cells escaping a natural cell deterioration ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Shapoval
not rated yet Mar 19, 2015
Father of Oncology discovers Iron-Related Genes involved in Blood Cancers. Although the specific cause of blood cancer is not known, a number of factors are associated with its development, researchers say. Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy. The Father of Oncology says that blood cancer is a form of iron lottery. At the cellular level, blood cancer occurs when cellular iron overload chaotically affects cellular molecules and organelles (DNA, chromosomes, mitochondria, etc). Blood cancer occurs when excessive iron is deposited in the bone marrow or in the lymphatic system. Blood cancer is always caused by iron-related genes (genes directly/indirectly involved in iron metabolism) and iron-related events (when excessive iron accumulates within blood-forming tissue due to various carcinogenic events) http://www.medica...s/183856 ; Medical Xpress & MNT & Vadim Shapoval

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.